Mestag Therapeutics, a UK-based biotech company using fibroblast immunology to develop treatments for patients with cancer and inflammatory disease, announced on Tuesday that it has been selected to present a late-breaking poster at the American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22, 2026 in San Diego, California.

A poster presentation titled 'MST-0312: Targeted LTBR Agonist Designed to Induce Tertiary Lymphoid Structures and High Endothelial Venules for the Treatment of Solid Tumors' will detail pre-clinical findings from the company's FAP-targeted LTBR agonist program, presented by Pascal Merchiers, chief development officer.

MST-0312 is a FAP-targeted LTBR agonist bispecific antibody designed to induce the formation of tertiary lymphoid structures (TLS) and high endothelial venules (HEV) in solid tumors. According to Mestag, a substantial body of clinical evidence demonstrates that the presence of TLS and HEV in tumors is associated with improved patient survival and enhanced responses to therapy, reflecting their role in facilitating lymphocyte access to the tumor and local education. LTBR activation is the key pathway driving TLS/HEV formation.

MST-0312 is anticipated to enter clinic mid-2026, with the initiation of the Phase 1 STARLYS trial.